Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18674 | 0.96 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1HTTSLC6A3 | |
| SCHEMBL905777 | 0.95 | HTT (0.59) | ALDH1A1MAPK1L3MBTL1HTTSLC6A3 | |
| SCHEMBL8488876 | 0.95 | HTT (0.59) | ALDH1A1MAPK1L3MBTL1HTTSLC6A3 | |
| SCHEMBL16197784 | 0.95 | HTT (0.59) | ALDH1A1MAPK1L3MBTL1HTTSLC6A3 | |
| SCHEMBL9814068 | 0.95 | HTT (0.59) | ALDH1A1MAPK1L3MBTL1HTTSLC6A3 | |
| SCHEMBL17004058 | 0.95 | HTT (0.59) | ALDH1A1MAPK1L3MBTL1HTTSLC6A3 | |
| SCHEMBL8491249 | 0.95 | HTT (0.59) | ALDH1A1MAPK1L3MBTL1HTTSLC6A3 | |
| SCHEMBL8854045 | 0.95 | HTT (0.59) | ALDH1A1MAPK1L3MBTL1HTTSLC6A3 | |
| SCHEMBL3335775 | 0.95 | HTT (0.59) | ALDH1A1MAPK1L3MBTL1HTTSLC6A3 | |
| SCHEMBL2932079 | 0.95 | HTT (0.59) | ALDH1A1MAPK1L3MBTL1HTTSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 667 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4368686-B1 | LUBRICITY IMPROVER COMPOSITION FOR FUEL OIL AND USE THEREOF | CHINA PETROLEUM & CHEM CORP (CN) | 2026-05-27 | — | — | EP | disclosed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122056912-A | Application of siRNA in preparing medicament for treating hepatitis | 苏州星曜坤泽生物制药有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4731229-A1 | SIRNA, CONJUGATE WHICH CONTAIN SIRNA, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hansoh Bio LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| US-20260103707-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA XIAMEN BIOPHARMA CO LTD (CN) | 2026-04-16 | — | — | US | disclosed |
| US-20260103708-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2026-04-16 | — | — | US | disclosed |
| EP-4534092-B1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-0608876-A1 | Ellipticine derivatives with antitumour activity | TANABE SEIYAKU CO., LTD. (JP) | 1994-08-03 | — | — | EP | disclosed |
| EP-0577659-A1 | CROSS-LINKING AGENT. | HOLMES MICHAEL JOHN (GB) | 1994-01-12 | — | — | EP | disclosed |
| EP-0546108-A4 | PRO-DRUGS FOR CCK ANTAGONISTS | — | 1993-09-22 | — | — | EP | disclosed |
| EP-0546108-A1 | PRO-DRUGS FOR CCK ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1993-06-16 | — | — | EP | disclosed |
| WO-1992017436-A1 | CROSS-LINKING AGENT | HOLMES, MICHAEL, JOHN (GB) | 1992-10-15 | — | — | WO | disclosed |
| WO-1992004038-A1 | PRO-DRUGS FOR CCK ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
| EP-0021676-B1 | 3-METHOXY-2-OXOAZETIDINE DERIVATIVES AND THEIR PRODUCTION | Takeda Chemical Industries, Ltd. (JP) | 1983-09-14 | — | — | EP | disclosed |
| EP-0034700-A1 | Salts of erythromycin A esters and preparation process | ABBOTT LABORATORIES (US) | 1981-09-02 | — | — | EP | disclosed |
| US-4264765-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1981-04-28 | — | — | US | disclosed |
| US-4098817-A | OXIDATION OF CYCLOALIPHATIC COMPOUNDS | PETRO-TEX CHEMICAL CORPORATION (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103708-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | NSUN2, HAVCR2, GALNT2 | ALDH1A1 2912/4885MAPK1 1812/4885L3MBTL1 457/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | ALDH1A1 210/4885MAPK1 1747/4885L3MBTL1 287/4885 |
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | ALDH1A1 3438/4885MAPK1 1763/4885L3MBTL1 424/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | ALDH1A1 4714/4885MAPK1 1056/4885L3MBTL1 1002/4885 |
| US-20260103707-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | GALNT10, FUT5, FUT6 | ALDH1A1 3104/4885MAPK1 2286/4885L3MBTL1 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.